X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Pfizer with IPCA Labs - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PFIZER vs IPCA LABS - Comparison Results

PFIZER    Change

Pfizer India is a 71% subsidiary of the world's largest pharmaceuticals company Pfizer Inc. Pfizer derives a larger share of its revenues from the pharmaceuticals division (81%). The company also has presence in the animal health (13%) and clinical d... More

IPCA LABS 
   Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PFIZER IPCA LABS PFIZER/
IPCA LABS
 
P/E (TTM) x 34.3 29.8 115.4% View Chart
P/BV x 5.1 3.5 143.2% View Chart
Dividend Yield % 0.7 0.1 507.4%  

Financials

 PFIZER   IPCA LABS
EQUITY SHARE DATA
    PFIZER
Mar-18
IPCA LABS
Mar-18
PFIZER/
IPCA LABS
5-Yr Chart
Click to enlarge
High Rs2,365695 340.1%   
Low Rs1,625400 406.3%   
Sales per share (Unadj.) Rs430.3260.2 165.4%  
Earnings per share (Unadj.) Rs78.719.0 414.9%  
Cash flow per share (Unadj.) Rs93.233.1 281.9%  
Dividends per share (Unadj.) Rs20.001.00 2,000.0%  
Dividend yield (eoy) %1.00.2 549.1%  
Book value per share (Unadj.) Rs586.5213.0 275.3%  
Shares outstanding (eoy) m45.75126.20 36.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.62.1 220.3%   
Avg P/E ratio x25.328.9 87.8%  
P/CF ratio (eoy) x21.416.6 129.2%  
Price / Book Value ratio x3.42.6 132.3%  
Dividend payout %25.45.3 482.1%   
Avg Mkt Cap Rs m91,27169,120 132.0%   
No. of employees `0002.613.3 19.8%   
Total wages/salary Rs m3,1437,359 42.7%   
Avg. sales/employee Rs Th7,484.82,477.4 302.1%   
Avg. wages/employee Rs Th1,195.0555.2 215.2%   
Avg. net profit/employee Rs Th1,369.1180.6 757.9%   
INCOME DATA
Net Sales Rs m19,68532,836 60.0%  
Other income Rs m1,143418 273.4%   
Total revenues Rs m20,82833,254 62.6%   
Gross profit Rs m5,0034,505 111.1%  
Depreciation Rs m6631,777 37.3%   
Interest Rs m4240 1.7%   
Profit before tax Rs m5,4792,905 188.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,878511 367.5%   
Profit after tax Rs m3,6012,394 150.4%  
Gross profit margin %25.413.7 185.2%  
Effective tax rate %34.317.6 194.9%   
Net profit margin %18.37.3 250.9%  
BALANCE SHEET DATA
Current assets Rs m24,16719,455 124.2%   
Current liabilities Rs m9,54410,076 94.7%   
Net working cap to sales %74.328.6 260.1%  
Current ratio x2.51.9 131.1%  
Inventory Days Days5598 56.3%  
Debtors Days Days2967 42.9%  
Net fixed assets Rs m9,51420,260 47.0%   
Share capital Rs m458252 181.3%   
"Free" reserves Rs m26,37526,633 99.0%   
Net worth Rs m26,83226,886 99.8%   
Long term debt Rs m252,340 1.1%   
Total assets Rs m36,90041,173 89.6%  
Interest coverage x1,305.513.1 9,969.6%   
Debt to equity ratio x00.1 1.1%  
Sales to assets ratio x0.50.8 66.9%   
Return on assets %9.86.4 152.7%  
Return on equity %13.48.9 150.7%  
Return on capital %20.410.8 189.7%  
Exports to sales %047.6 0.0%   
Imports to sales %014.9 0.0%   
Exports (fob) Rs mNA15,642 0.0%   
Imports (cif) Rs mNA4,884 0.0%   
Fx inflow Rs m2215,642 0.1%   
Fx outflow Rs m1,4894,884 30.5%   
Net fx Rs m-1,46610,759 -13.6%   
CASH FLOW
From Operations Rs m3,3183,411 97.3%  
From Investments Rs m-2,383-1,354 176.0%  
From Financial Activity Rs m-1,104-1,304 84.6%  
Net Cashflow Rs m-169753 -22.4%  

Share Holding

Indian Promoters % 0.0 45.9 -  
Foreign collaborators % 63.9 0.0 -  
Indian inst/Mut Fund % 7.5 11.4 65.8%  
FIIs % 4.9 25.3 19.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 23.7 17.4 136.2%  
Shareholders   85,207 36,892 231.0%  
Pledged promoter(s) holding % 0.0 2.1 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PFIZER With:   SHASUN PHARMA  DR. REDDYS LAB  TORRENT PHARMA  UNICHEM LAB  MERCK LTD  

Compare PFIZER With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex, Nifty Close at Record Highs; Healthcare and Power Stocks Witness Buying(Closing)

Indian share markets continued to trade on a flat during closing hours of trade and ended the day marginally higher to close at fresh record high levels.

Related Views on News

IPCA LABS Announces Quarterly Results (1QFY19); Net Profit Down 423.6% (Quarterly Result Update)

Aug 13, 2018 | Updated on Aug 13, 2018

For the quarter ended June 2018, IPCA LABS has posted a net profit of Rs 655 m (down 423.6% YoY). Sales on the other hand came in at Rs 9 bn (up 19.8% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

PFIZER Announces Quarterly Results (1QFY19); Net Profit Up 60.6% (Quarterly Result Update)

Aug 3, 2018 | Updated on Aug 3, 2018

For the quarter ended June 2018, PFIZER has posted a net profit of Rs 918 m (up 60.6% YoY). Sales on the other hand came in at Rs 5 bn (up 18.4% YoY). Read on for a complete analysis of PFIZER's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

This is a Must-Have Stock for Your Portfolio(The 5 Minute Wrapup)

Aug 8, 2018

Tanushree just released the permanent wealth blueprint report. This report includes three safe and steady stocks. I like one in particular. Here's why

Trading in These Times: 8% Gains in 3 Days!(Profit Hunter)

Aug 9, 2018

Here are 2 stocks you can buy right now! And there are plenty more opportunities to come...

Only on WhatsApp, a Weaker Rupee Means a Weaker India(Vivek Kaul's Diary)

Aug 16, 2018

While dollar crossing Rs 70 will have its repercussions, the world isn't exactly coming to an end.

Why HDFC Equity Fund Disappointed Its Investors(Outside View)

Aug 9, 2018

Though popular, HDFC Equity Fund is not among the best performers anymore. Here is the reason behind its underperformance that has left investors disappointed.

HDFC AMC Makes 65% Listing Gains! Should It Attract Mutual Fund Investors?(Outside View)

Aug 8, 2018

PersonalFN explains if investors should invest in schemes of HDFC Mutual Fund looking at the listing gains of HDFC AMC.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PFIZER SHARE PRICE


Aug 21, 2018 (Close)

TRACK PFIZER

COMPARE PFIZER WITH

MARKET STATS